----

|                                                                |
|----------------------------------------------------------------|
|                                                                |  |
| Delaware                                                       | 63-0860407 |
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |

|                                                                                         |
|-----------------------------------------------------------------------------------------|
|                                                                                         |  |  |  |  |
| Title of Each Class ofSecurities to be Registered                                       | Amount to be Registered (1) | Proposed Maximum Offering Price Per Share (2) | Proposed Maximum Aggregate Offering Price (2) | Amount of Registration Fee |
| Common Stock, par value $.01 per share, issuable upon exercise of Common Stock Warrants | 8,151,265 | $41.40 | $337,462,371 | $39,214 |

|     |                                                                                                                                                                                                                                                                                                                                                                           |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”) this registration statement also covers any additional shares of common stock of HealthSouth Corporation that may become issuable as a result of any stock splits, stock dividends, recapitalizations, anti-dilution adjustments or other similar transactions. |

|     |                                                                                                                                                                                                                                                                                                                               |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act based on a warrant exercise price of $41.40 per share with respect to shares of common stock issuable upon exercise of warrants to acquire 8,151,265 shares of common stock of HealthSouth Corporation. |

----

----

|                                                   |
|---------------------------------------------------|
|                                                   |  |
|                                              | Page |
| About This Prospectus                             | 1 |
| Forward-Looking Statements                        | 2 |
| Prospectus Summary                                | 4 |
| Risk Factors                                      | 8 |
| Use of Proceeds                                   | 30 |
| Determination of Offering Price                   | 30 |
| Plan of Distribution                              | 31 |
| Description of Securities                         | 32 |
| Where You Can Find More Information               | 36 |
| Incorporation of Certain Information by Reference | 37 |
| Legal Matters                                     | 38 |
| Experts                                           | 38 |

----

----

|         |                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | each of the factors discussed under the heading “Risk Factors” beginning on page 8 of this prospectus and in Item 1A, Risk Factors, of our Annual Report on Form 10‑K for the year ended December 31, 2014, as may be updated or supplemented in our other filings with the SEC in the future that are incorporated herein and into any prospectus supplement by reference; |

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | changes in the rules and regulations of the healthcare industry at either or both of the federal and state levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction such as the reinstatement of the “75% Rule” or the introduction of site neutral payments with skilled nursing facilities for certain conditions, and related increases in the costs of complying with such changes; |

|         |                                                                                                                                                                                                                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our ability to obtain and retain favorable arrangements with third-party payors and our exposure to the effects of Medicare claims audits for services previously provided; |

|         |                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | increased costs of regulatory compliance and compliance monitoring in the healthcare industry, including the costs of investigating and defending asserted claims, whether meritorious or not; |

|         |                                                                                                                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and the impact on our labor expenses from potential union activity and staffing recruitment and retention; |

|         |                                                                                       |
|---------|---------------------------------------------------------------------------------------|
| • | competitive pressures in the healthcare industry and our response to those pressures; |

|         |                                                                                                                                                                                                                                                                                             |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, and productivity improvements arising from the related operations; |

|         |                                                                                                                                                                                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including the ongoing investigations initiated by the U.S. Department of Health and Human Services, Office of the Inspector General; |

|         |                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | increased costs of defending and insuring against alleged professional liability and other claims and the ability to predict the costs related to such claims; |

|         |                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------|
| • | potential incidents affecting the proper operation, availability, or security of our information systems; |

----

|         |                                                                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the price of our common or preferred stock as it affects our willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; |

|         |                                                                                           |
|---------|-------------------------------------------------------------------------------------------|
| • | our ability and willingness to continue to declare and pay dividends on our common stock; |

|         |                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to successfully integrate Encompass Home Health and Hospice, including the realization of anticipated benefits from the acquisition and avoidance of unanticipated difficulties, costs, or liabilities that could arise from the acquisition or integration; |

|         |                                                                 |
|---------|-----------------------------------------------------------------|
| • | our ability to attract and retain key management personnel; and |

|         |                                                                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | general conditions in the economy and capital markets, including any instability or uncertainty related to governmental impasse over approval of the United States federal budget or an increase to the debt ceiling. |

----

----

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | home health services - a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. Encompass also provides specialized home care services in Texas and Kansas for pediatric patients with severe medical conditions. Encompass’ home health services have historically represented a substantial portion of its revenue. For the year ended December 31, 2014, these services represented approximately 94% of Encompass’ total revenues. |
|         |                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | hospice services - primarily in-home services to terminally ill patients and their families to address the patients’ physical needs, including pain control and symptom management, and to provide emotional and spiritual support. For the year ended December 31, 2014, these services represented approximately 6% of Encompass’ total revenues. |

----

|                                              |
|----------------------------------------------|
|                                              |  |
| Issuer                                       | HealthSouth Corporation. |
| Securities Offered                           | Up to 8,151,265 shares of our common stock underlying the warrants. |
| Warrant Expiration Date                      | Each warrant is exercisable at any time until 5:00 p.m., New York City time, on January 17, 2017. |
| Exercise Price                               | Each warrant entitles its holder to purchase one share of our common stock at an exercise price of $41.40, subject to adjustment as described in this prospectus and in the Warrant Agreement. In lieu of paying the aggregate exercise price in cash, a holder may elect, provided that at the time of the exercise the market price of our common stock exceeds the exercise price, to exercise warrants by means of a cashless exercise in which shares otherwise issuable upon exercise are withheld to satisfy the exercise price due. See “Description of Securities—Description of Warrants—Exercise of Warrants.” |
| Adjustments                                  | The exercise price of each warrant, and the number of shares of common stock purchasable upon the exercise of each warrant, may be adjusted, subject to certain exceptions, upon (a) a dividend or distribution of our common stock, (b) a subdivision of our common stock, (c) a combination of our common stock, (d) a reclassification of our common stock or (e) a distribution to all of our stockholders of assets or other securities of the Company. See “Description of Securities—Description of Warrants—Adjustments.” |
| Common stock outstanding after this offering | 95,939,938 shares, assuming the exercise of all of the warrants for cash, based on the number of shares of common stock outstanding as of December 31, 2014. |
| No Fractional Shares                         | We will not issue fractional shares of our common stock upon the exercise of the warrants. In lieu of issuing fractional shares, the Company will pay the holder an amount in cash equal to the market price of our common stock as provided herein. See “Description of Securities—Description of Warrants—Exercise of Warrants.” |
| Warrant Holder not a Stockholder             | Prior to their exercise, the warrants do not entitle the holders to any voting or other rights as are accorded to our stockholders. |
| Redemption                                   | The warrants are not redeemable by the Company or any other person. |
| Registration of Common Stock with the SEC    | Pursuant to the Warrant Agreement and the terms of the Settlement under which we entered into the Warrant Agreement, we are required to file a registration statement with the SEC under the Securities Act registering the issuance of the shares of common stock underlying the warrants to the holders of the warrants. We filed a registration statement, of which this prospectus forms a part, pursuant to this obligation. Furthermore, the terms of the Warrant Agreement require us to use our reasonable best efforts to cause the registration statement to remain continually effective until all of the warrants have been exercised or have expired. See “Description of Securities—Description of Warrants—Registration of Common Stock with the SEC.” |
| Use of Proceeds                              | We may receive cash consideration in connection with the exercise of the warrants if the holders thereof make a cash payment for the exercise price rather than exercise the warrants through a cashless exercise, as provided in the Warrant Agreement. If the warrants are fully exercised for cash, we will receive gross proceeds of $337,462,371. We intend to use any cash proceeds for general corporate purposes. |
| NYSE Symbol for Common Stock                 | HLS. |

----

|                          |
|--------------------------|
|                          |  |
| NYSE Symbol for Warrants | We have applied to list the warrants on the New York Stock Exchange under the symbol “HLSWS.” See “Description of Securities—Description of Warrants—Listing.” |
| Risk Factors             | See “Risk Factors” beginning on page 8 of this prospectus and the risk factors discussed in any prospectus supplement and in our current and future SEC filings that are incorporated by reference herein and therein for a discussion of the factors you should carefully consider before deciding whether to purchase our securities. |
|                     |   |

----

----

----

----

----

|         |
|---------|
|         |  |  |
| 2015-16 |   | 2017-19 |
| 0.2%    |   | 0.75% |

----

----

----

|         |                                              |
|---------|----------------------------------------------|
| • | licensure, certification, and accreditation; |

|         |                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements); |

----

|         |                                  |
|---------|----------------------------------|
| • | coding and billing for services; |

|         |                                                                           |
|---------|---------------------------------------------------------------------------|
| • | requirements of the 60% compliance threshold under the 2007 Medicare Act; |

|         |                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------|
| • | relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws; |

|         |                          |
|---------|--------------------------|
| • | quality of medical care; |

|         |                                                        |
|---------|--------------------------------------------------------|
| • | use and maintenance of medical supplies and equipment; |

|         |                                                                      |
|---------|----------------------------------------------------------------------|
| • | maintenance and security of patient information and medical records; |

|         |                                                                              |
|---------|------------------------------------------------------------------------------|
| • | acquisition and dispensing of pharmaceuticals and controlled substances; and |

|         |                                          |
|---------|------------------------------------------|
| • | disposal of medical and hazardous waste. |

----

----

----

----

|         |                                                                                                                                                                                                                                                          |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | limitations, including state CONs as well as CMS and other regulatory approval requirements, on our ability to complete such acquisitions, particularly those involving not-for-profit providers, on terms, timetables, and valuations reasonable to us; |

|         |                                                                                 |
|---------|---------------------------------------------------------------------------------|
| • | limitations in obtaining financing for acquisitions at a cost reasonable to us; |

|         |                                                                                                                                                                                       |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | difficulties integrating acquired operations, personnel, and information systems, and in realizing projected revenues, efficiencies and cost savings, or returns on invested capital; |

|         |                                                                                          |
|---------|------------------------------------------------------------------------------------------|
| • | entry into markets, businesses or services in which we may have little or no experience; |

|         |                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------|
| • | diversion of business resources or management’s attention from ongoing business operations; and |

|         |                                                                                                                                                                                               |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | exposure to undisclosed or unforeseen liabilities of acquired operations, including liabilities for failure to comply with healthcare laws and anti-trust considerations in specific markets. |

----

----

----

|         |                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | limiting our ability to borrow additional amounts to fund working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy and other general corporate purposes; |

|         |                                                                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | making us more vulnerable to adverse changes in general economic, industry and competitive conditions, in government regulation and in our business by limiting our flexibility in planning for, and making it more difficult for us to react quickly to, changing conditions; |

|         |                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------|
| • | placing us at a competitive disadvantage compared with competing providers that have less debt; and |

|         |                                                                                                                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | exposing us to risks inherent in interest rate fluctuations for outstanding amounts under our credit facility, which could result in higher interest expense in the event of increases in interest rates. |

|         |                                  |
|---------|----------------------------------|
| • | incur or guarantee indebtedness; |

|         |                                                                                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------------|
| • | pay dividends on, or redeem or repurchase, our capital stock; or repay, redeem or repurchase our subordinated obligations; |

|         |                                                 |
|---------|-------------------------------------------------|
| • | issue or sell certain types of preferred stock; |

----

|         |                   |
|---------|-------------------|
| • | make investments; |

|         |                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------|
| • | incur obligations that restrict the ability of our subsidiaries to make dividends or other payments to us; |

|         |              |
|---------|--------------|
| • | sell assets; |

|         |                                         |
|---------|-----------------------------------------|
| • | engage in transactions with affiliates; |

|         |                       |
|---------|-----------------------|
| • | create certain liens; |

|         |                                             |
|---------|---------------------------------------------|
| • | enter into sale/leaseback transactions; and |

|         |                                                                         |
|---------|-------------------------------------------------------------------------|
| • | merge, consolidate, or transfer all or substantially all of our assets. |

----

----

----

----

----

----

----

----

----

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | if the holder holds the warrants being exercised through The Depositary Trust Company’s book-entry transfer facilities, by same-day or next-day credit to the Depositary for the account of such holder or for the account of a participant in the Depositary the number of shares to which such holder is entitled, in each case registered in such name and delivered to such account as directed in the warrant exercise notice by such holder or by the direct participant in the Depositary through which such holding is acting, or |

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | if such holder holds the warrants being exercised in the form of book-entry warrants, a book-entry interest in the shares registered on the books of the Company’s transfer agent or, at the Company’s option, by delivery to the address designated by such holder in its warrant exercise notice of a physical certificate representing the number of shares to which such holder is entitled, in fully registered form, registered in such name or names as may be directed by such holder. |

|         |                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------|
| • | pay a dividend in shares of common stock or make a distribution on common stock consisting of shares of common stock; |

|         |                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------|
| • | subdivide its outstanding shares of common stock into a greater number of shares of common stock; |

|         |                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------|
| • | combine its outstanding shares of common stock into a smaller number of shares of common stock; |

|         |                                                                                       |
|---------|---------------------------------------------------------------------------------------|
| • | issue, in a reclassification of the common stock, other securities of the Company; or |

|         |                                                                                                                                                                                                                                                         |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | distribute to all holders of common stock any assets (other than cash dividends paid), debt securities or preferred stock of the Company or any options, warrants or other rights to acquire assets, debt securities or preferred stock of the Company. |

----

----

----

----

|         |                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------|
| • | Our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 2, 2015; |

|         |                                                                                                                                        |
|---------|----------------------------------------------------------------------------------------------------------------------------------------|
| • | Our Current Reports on Form 8-K filed with the SEC on January 2, 2015, January 23, 2015, January 29, 2015, and February 20, 2015; |

|         |                                                                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | The information contained in our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 1, 2014 and incorporated into Part III of our Annual Report on Form 10-K for the year ended December 31, 2013; and |

|         |                                                                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Our Registration Statement on Form 8-A, filed with the SEC on September 13, 2006, describing our common stock, and any amendment or report filed with the SEC for the purpose of updating the description. |

----

----

----

----

----

----

----

|                                                     |
|-----------------------------------------------------|
|                                                     |  |  |  |  |
| Securities and Exchange Commission Registration Fee | $ | 39,214 |  |   |
| Accounting Fees and Expenses                        | 10,000 |  |   |
| Legal Fees and Expenses                             | 25,000 |  |   |
| Warrant Agent Fees and Expenses                     | 3,200,000 |  | * |
| Printing and Mailing Fees and Expenses              | 135,800 |  |   |
| Total                                               | $ | 3,410,014 |  |   |

----

----

----

----

----

|                                                                       |
|-----------------------------------------------------------------------|
|                                                                       |  |  |
| Signature                                                        | Capacity  | Date  |
|                                                                  |   |   |
| /s/ Jay Grinney Jay Grinney                                      | President and Chief Executive Officer and Director | March 6, 2015 |
|                                                                  |   |   |
| /s/ Douglas E. Coltharp       Douglas E. Coltharp | Executive Vice President and Chief Financial Officer | March 6, 2015 |
|                                                                  |   |   |
| /s/ Andrew L. Price       Andrew L. Price         | Chief Accounting Officer | March 6, 2015 |
|                                                                  |   |   |
| /s/ Leo I. Higdon, Jr. Leo I. Higdon, Jr.                        | Chairman of the  Board of Directors | March 6, 2015 |
|                                                                  |   |   |
| /s/ John W. Chidsey John W. Chidsey                              | Director | March 6, 2015 |
|                                                                  |   |   |
| /s/ Donald L. Correll Donald L. Correll                          | Director | March 6, 2015 |
| /s/ Yvonne M. Curl Yvonne M. Curl                                | Director | March 6, 2015 |
| /s/ Charles M. Elson Charles M. Elson                            | Director | March 6, 2015 |
|                                                                  |   |   |
| /s/ Joan E. Herman Joan E. Herman                                | Director | March 6, 2015 |
|                                                                  |   |   |
| /s/ Leslye G. Katz Leslye G. Katz                                | Director | March 6, 2015 |
|                                                                  |   |   |
| /s/ John E. Maupin, Jr. John E. Maupin, Jr.                      | Director | March 6, 2015 |
|                                                                  |   |   |
| /s/ L. Edward Shaw, Jr. L. Edward Shaw, Jr.                      | Director | March 6, 2015 |

----

|        |
|--------|
|        |  |  |
| No.    | Description |   |
| 4.1    | Restated Certificate of Incorporation of HealthSouth Corporation, as filed in the Office of the Secretary of State of the State of Delaware on May 21, 1998 (incorporated by reference to HealthSouth’s Annual Report on Form 10-K filed with the SEC on June 27, 2005). |
| 4.2    | Certificate of Amendment to the Restated Certificate of Incorporation of HealthSouth Corporation, as filed in the Office of the Secretary of State of the State of Delaware on October 25, 2006 (incorporated by reference to Exhibit 3.1 to HealthSouth’s Current Report on Form 8-K filed on October 31, 2006). |
| 4.3    | Amended and Restated Bylaws of HealthSouth Corporation, effective as of October 30, 2009 (incorporated by reference to Exhibit 3.3 to HealthSouth’s Quarterly Report on Form 10-Q filed on November 4, 2009). |
| 4.4    | Certificate of Designations of 6.50% Series A Convertible Perpetual Preferred Stock, as filed with the Secretary of State of the State of Delaware on March 7, 2006 (incorporated by reference to Exhibit 3.1 to HealthSouth’s Current Report on Form 8-K filed on March 9, 2006). |
| 4.5    | Warrant Agreement, dated as of September 30, 2009, among HealthSouth Corporation and Computershare Inc. and Computershare Trust Company, N.A., jointly and severally as Warrant Agent (incorporated by reference to Exhibit 4.1 to HealthSouth’s Registration Statement on Form 8-A filed on October 1, 2009). |
| 4.6.1  | Indenture, dated as of December 1, 2009, between HealthSouth Corporation and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth’s 8.125% Senior Notes due 2020, 7.250% Senior Notes due 2018, 7.750% Senior Notes due 2022 and 5.75% Senior Notes due 2024 (incorporated by reference to Exhibit 4.7.1 to HealthSouth’s Annual Report on Form 10-K filed on February 23, 2010.) |
| 4.6.2  | First Supplemental Indenture, dated December 1, 2009, among HealthSouth Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth’s 8.125% Senior Notes due 2020 (incorporated by reference to Exhibit 4.7.2 to HealthSouth’s Annual Report on Form 10-K filed on February 23, 2010). |
| 4.6.3  | Third Supplemental Indenture, dated October 7, 2010, among HealthSouth Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth’s 7.750% Senior Notes due 2022 (incorporated by reference to Exhibit 4.3 to HealthSouth’s Current Report on Form 8-K filed on October 12, 2010). |
| 4.6.4  | Fourth Supplemental Indenture, dated September 11, 2012, among HealthSouth Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as successor trustee to The Bank of Nova Scotia Trust Company of New York, relating to HealthSouth’s 5.75% Senior Notes due 2024 (incorporated by reference to Exhibit 4.2 to HealthSouth’s Current Report on Form 8-K filed on September 11, 2012). |
| 4.7    | Indenture, dated November 18, 2013, among HealthSouth Corporation and Wells Fargo Bank, National Association, as trustee, relating to HealthSouth’s 2.00% Convertible Senior Subordinated Notes due 2043 (incorporated by reference to Exhibit 4.1 to HealthSouth’s Current Report on Form 8-K filed on November 19, 2013). |
| 5.1    | Opinion of Stephen D. Leasure, Esq., as to the validity of the securities.* |
| 23.1   | Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.* |
| 23.2   | Consent of Stephen D. Leasure, Esq. (included in Exhibit 5.1).* |
| 24.1   | Power of Attorney (included as part of signature page). |
|   | * Filed herewith. |   |